A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
UCL ranked number one collaborator in the UK for biomedical industry partnerships
23 May 2013
UCL has ranked the leading institution in the UK as a partner for industry within the biotechnology and pharmaceutical sectors compiled by the Nature Biotechnology journal.
UCL was ranked the top university in the UK and third in the world – ranking only behind Harvard University and the University of Texas in the US – for partnerships including Ark Therapeutics, Eisai, Oxford Pharmascience and Horizon Discovery.
Of the 387 public-private partnerships analysed by the journal across a range of institutions, cancer and infectious diseases were the most significant areas of interest, followed by diagnostics.
“Our placing in this ranking is testament to the strong emphasis UCL has put on building strong relationships with industry for many years now, with our efforts accelerating with the implementation of a comprehensive enterprise strategy,” said Professor Stephen Caddick, Vice-Provost for Enterprise at UCL.
“The quality of research in the biomedical sciences emerging from UCL is world-leading, and this, too, has made us a natural choice for attracting partners looking to work with us to ensure such innovations benefit patients directly,” he added.